To read the full story, subscribe or sign in.

Beckley Atai deal to go forth on positive phase IIb depression data

July 1, 2025

The joining of psychedelic specialists Beckley Psytech Ltd. and Atai Life Sciences can now go ahead after the pair announced positive top-line results from the phase IIb study of BPL-003, an intranasal formulation of 5-MeO-DMT benzoate.

BioWorld Clinical Neurology/psychiatric Small molecule Europe

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 17, 2025.

Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

BioWorld

The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...

PHD inhibitors reported in Akebia Therapeutics patent

BioWorld Science

Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.